Advertisement

Stem Cell Reviews and Reports

, Volume 8, Issue 2, pp 299–304 | Cite as

Stem Cell Policy Exceptionalism: Proceed with Caution

  • Geoffrey P. Lomax
  • Steven R. Peckman
Article

Abstract

The term “stem cell exceptionalism” has been used to characterize the policy response to controversies surrounding human embryonic stem cell research. For example, governments and funding agencies have adopted policies governing the derivation and use of human embryonic stem cell lines. These policies have effectively served to fill gaps in existing guidelines and regulations and signal that scientists are committed to a responsible framework for the conduct of research involving human embryos. Recent publications discuss whether ethical and policy issues associated with induced pluripotent cells (iPSCs) from non-embryonic sources create a need for further policy intervention. We suggest many of the issues identified by commentators may be addressed through the application of established policy frameworks governing the use of tissue, human stem cells, and research participation by human research subjects. To the extent, iPSC research intersects with hESC research (e.g. the creation of human gametes and/or embryos), the policy framework governing hESC appears sufficiently robust at this time.

Keywords

Stem cell Ethics Research oversight Induced pluripotent cells Human subjects Embryonic stem cell Research policy Human subjects 

Notes

Acknowledgments

The authors would like to acknowledge the time and effort taken by the reviewers to proved comprehensive comments.

References

  1. 1.
    Snead, O. (2005). Preparing the groundwork for a responsible debate on stem cell research and human cloning. New England Law Review, 39, 479.Google Scholar
  2. 2.
    Stayn, S. (2006). A guide to state laws on hESC research and a call for interstate dialogue. Medical Research Law & Policy, 05(21), 718–725.Google Scholar
  3. 3.
    Sage, W. (2010). Will embryonic stem cells change health policy? Journal of Law, Medicine & Ethics, Law, Science and Innovation: The Embryonic Stem Cell Controversy, summer.Google Scholar
  4. 4.
    NAS. (2005). Guidelines for human embryonic stem cell research. IOM National Research Council (U.S.). Committee on Guidelines for Human Embryonic Stem Cell Research. Washington: The National Academies Press.Google Scholar
  5. 5.
    Robertson, J. (2010). Embryo stem cell research: ten years of controversy. Journal of Law, Medicine & Ethics, Science and Innovation: The Embryonic Stem Cell Controversy, Summer.Google Scholar
  6. 6.
    Lo, B., Parham, L., et al. (2010). Cloning mice and men: prohibiting the use of iPS cells for human reproductive cloning. Cell Stem Cell, 6(1), 16–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Caulfield, T., Scott, C., et al. (2010). Stem cell research policy and iPS cells. Nature Methods, 7(1), 28–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Aalto-Setala, K., Conklin, B. R., et al. (2009). Obtaining consent for future research with induced pluripotent cells: opportunities and challenges. PLoS Biology, 7(2), 204–208.CrossRefGoogle Scholar
  9. 9.
    Zarzeczny, A., Scott, C., et al. (2009). iPS cells: mapping the policy issues. Cell, 139(6), 1032–1037.PubMedCrossRefGoogle Scholar
  10. 10.
    Sugarman, J. (2008). Human stem cell ethics: beyond the embryo. Cell Stem Cell, 2(6), 529–533.PubMedCrossRefGoogle Scholar
  11. 11.
    Condic, M. L., & Rao, M. (2008). Regulatory issues for personalized pluripotent cells. Stem Cells, 26(11), 2753–2758.PubMedCrossRefGoogle Scholar
  12. 12.
    Gunsalus, C. K., Bruner, E. M., et al. (2006). Mission creep and the IRB world. Science, 312(5779), 1441.PubMedCrossRefGoogle Scholar
  13. 13.
    Kawakami, M., Sipp, D., & Kato, K. (2010). Regulatory impacts on stem cell research in Japan. Cell Stem Cell, 7:6(5), 415–418.CrossRefGoogle Scholar
  14. 14.
    Fink, D. W., Jr. (2009). FDA regulation of stem cell-based products. Science, 324(5935), 1662–1663.PubMedCrossRefGoogle Scholar
  15. 15.
    Carpenter, M. K., Frey-Vasconcells, J., et al. (2009). Developing safe therapies from human pluripotent stem cells. Nature Biotechnology, 27(7), 606–613.PubMedCrossRefGoogle Scholar
  16. 16.
    Rao, M., & Condic, M. L. (2009). Musings on genome medicine: is there hope for ethical and safe stem cell therapeutics? Genome Medicine, 1(7), 70.PubMedCrossRefGoogle Scholar
  17. 17.
    Lau, D., et al. (2008). Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell, 3(6), 591–594.PubMedCrossRefGoogle Scholar
  18. 18.
    CIRM (2011). Ethical and Policy Considerations for A Pluripotent Stem Cell Resource Center 2011 Update. Available at http://www.cirm.ca.gov/files/MeetingReports/SWG_April_2011_6_28_2011.pdf (accessed July 19, 2011).
  19. 19.
    Mascalzoni, D., Hicks, A., et al. (2008). Informed consent in the genomics era. PLoS Medicine, 5(9), 1302–1305.CrossRefGoogle Scholar
  20. 20.
    Helft, P. R., Champion, V. L., et al. (2007). Cancer patients’ attitudes toward future research uses of stored human biological materials. Journal of Empirical Research on Human Research Ethics, 2(3), 15–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Malin, B., & Loukides, G. (2011). Identifiability in biobanks: models, measures, and mitigation strategies. Hum Genet. 2011 Jul 8. [Epub ahead of print].Google Scholar
  22. 22.
    Baylis, F. (2008). Animal eggs for stem cell research: a path not worth taking. The American Journal of Bioethics, 8(12), 18–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Winickoff, D. E., & Winickoff, R. N. (2003). The charitable trust as a model for genomic biobanks. The New England Journal of Medicine, 349, 1180–1184.PubMedCrossRefGoogle Scholar
  24. 24.
    Holm, S. (2006). Who should control the use of human embryonic stem cell lines: a defense of the donors’ ability to control. Bioethical Inquiry, 3, 55–68.CrossRefGoogle Scholar
  25. 25.
    Wendler, D. (2006). One-time general consent for research on biological samples. BMJ, 332(7540), 544–547.PubMedCrossRefGoogle Scholar
  26. 26.
    Simon, C., & L’Heureux, J. (2011). Active choice but not too active: Public perspectives on biobank consent models. Genetics in Medicine, Published Ahead-of-Print.Google Scholar
  27. 27.
    Caulfield, T. (2007). Biobanks and blanket consent: the proper place of the public good and public perception rationales. Kings Law Journal, 18, 209–226.Google Scholar
  28. 28.
    Presentation by Chris Hempel PRIM&R Advancing ethical research conference Tuesday December 7, 2010. Also, see http://addiandcassi.com/.
  29. 29.
    UNESCO (2003) International declaration on human genetic data. United Nations Educational, Scientific, and Cultural Organization and ESHG. Eur J Hum Genet, 11(Suppl 2), S8–10.Google Scholar
  30. 30.
    National Cancer Institute. (2007). National Cancer Institute best practices for biospecimen resources.Google Scholar
  31. 31.
    National Institutes of Health. (2009). National Institutes of Health guidelines on human stem cell research.Google Scholar
  32. 32.
    Rothstein, M. A. (2007). Genetic exceptionalism and legislative pragmatism. The Journal of Law, Medicine & Ethics, 35(2 Suppl), 59–65.CrossRefGoogle Scholar
  33. 33.
    Caulfield, T., Zarzeczny, A., et al. (2009). The stem cell research environment: a patchwork of patchworks. Stem Cell Review and Reports, 5(2), 82–88.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.California Institute for Regenerative MedicineSan FranciscoUSA
  2. 2.Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell ResearchUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations